Table 1.
Reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 of adjuvant arthritis
| Experiment 1 | Arthritis score | Paw volume | ||
|---|---|---|---|---|
| Treatment | Day 19 | Day 28 | Day 19 | Day 28 |
| AA/PBS | -- | -- | -- | -- |
| AA/PBS-liposomes | +23% ± 29.4% | +36% ± 56.5% | + 2% ± 38.8% | +47% ± 62.3% |
| AA/DxM-P | -51% ± 17.8% | + 4% ± 41.7% | -65% ± 14.0% | -13% ± 26.4% |
| AA/liposomal DxM-P | -95% ± 3.2%++ ## | -54% ± 28.7% | -92% ± 7.4%++ # | -73% ± 17.3% + |
| Experiment 2/3 | Arthritis score | Paw volume | ||
| Treatment | Day 19 | Day 29* | Day 19 | Day 29* |
| AA/PBS | -- | -- | -- | -- |
| AA/PBS-liposomes | +15% ± 19.8% | +23% ± 20.3% | ||
| AA/DxM-P | -67% ± 16.4% + # | -52% ± 21.8% + # | ||
| AA/liposomal DxM-P | -90% ± 5.0%++ ## | -87% ± 6.6.%++ ## | ||
| AA/liposomal DxM-P 1× * | -48% ± 23.9% | -15% ± 29.6% | -63% ± 24.6% | -35% ± 22.6% |
Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with PBS-liposomes, free DxM-P (3 × 1 mg/kg; Days 14, 15 and 16), or liposomal DxM-P (3 × 1 mg/kg; Days 14, 15 and 16) compared to AA/PBS (Experiment 1 corresponds to the data in Figure 1). For comparison, the effects of treatment with single-dose liposomal DxM-P (1 × 1 mg/kg; Day 14; Experiment 3) are shown. * results from a separate subgroup of animals (named Experiment 3 for clarity) from the same arthritis study with similar disease severity on Days 19 and 20 as the other subgroup of animals (named Experiment 2).
Data are expressed as means ± standard error of the mean.
+ P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. PBS-liposomes.